Table 1.
Detailed clinical information for all HCC patients from TCGA.
| Characteristic | Low Expression of ZCCHC17 | High Expression of ZCCHC17 | p |
|---|---|---|---|
| n | 187 | 187 | |
| T stage, n (%) | 0.021 | ||
| T1 | 105 (28.3%) | 78 (21%) | |
| T2 | 38 (10.2%) | 57 (15.4%) | |
| T3 | 39 (10.5%) | 41 (11.1%) | |
| T4 | 4 (1.1%) | 9 (2.4%) | |
| N stage, n (%) | 0.059 | ||
| N0 | 130 (50.4%) | 124 (48.1%) | |
| N1 | 0 (0%) | 4 (1.6%) | |
| M stage, n (%) | 1.000 | ||
| M0 | 130 (47.8%) | 138 (50.7%) | |
| M1 | 2 (0.7%) | 2 (0.7%) | |
| Pathologic stage, n (%) | 0.032 | ||
| Stage I | 101 (28.9%) | 72 (20.6%) | |
| Stage II | 37 (10.6%) | 50 (14.3%) | |
| Stage III | 37 (10.6%) | 48 (13.7%) | |
| Stage IV | 2 (0.6%) | 3 (0.9%) | |
| Tumor status, n (%) | 0.305 | ||
| Tumor free | 106 (29.9%) | 96 (27%) | |
| With tumor | 71 (20%) | 82 (23.1%) | |
| Gender, n (%) | 0.658 | ||
| Female | 58 (15.5%) | 63 (16.8%) | |
| Male | 129 (34.5%) | 124 (33.2%) | |
| Age, n (%) | 0.277 | ||
| <=60 | 83 (22.3%) | 94 (25.2%) | |
| >60 | 104 (27.9%) | 92 (24.7%) | |
| Histologic grade, n (%) | 0.032 | ||
| G1 | 32 (8.7%) | 23 (6.2%) | |
| G2 | 95 (25.7%) | 83 (22.5%) | |
| G3 | 56 (15.2%) | 68 (18.4%) | |
| G4 | 2 (0.5%) | 10 (2.7%) | |
| AFP(ng/ml), n (%) | 0.336 | ||
| <=400 | 116 (41.4%) | 99 (35.4%) | |
| >400 | 30 (10.7%) | 35 (12.5%) | |
| Vascular invasion, n (%) | 0.086 | ||
| No | 117 (36.8%) | 91 (28.6%) | |
| Yes | 50 (15.7%) | 60 (18.9%) |
The bold values represent different pathological features.
The P value in bold indicates that the P value is statistically significant.